 Home </wps/find/homepage.cws_home> | Site map
</wps/find/sitemap.cws_home/sitemap> | Elsevier websites
</wps/find/elsevierwebsites.cws_home/elsevierwebsites> | Alerts
</wps/find/home_content.cws_home/alertingservices>
	Elsevier 		

	Product information search 	
	Search all Elsevier sites 	
Search <javascript:submitSearchForm(document.forms['searchForm'])> 	
Advanced Product Search
</wps/find/advproductsearch.cws_home?action=product_search&search=no>

	

Go to Elsevier home page </wps/find/homepage.cws_home>

	
	Products
</wps/find/subject_area_browse.cws_home/?sh1State=-null-SAR-SAA-SAC-SAD-SAF-SA1-SAI-SAJ-SAK-SAQ-SAP-SAB-SAE-SAL-SAN-SAO-SAG-SAH-SAM&sh2State=&allParents=y&showAll=y>
	

	Molecular Immunology
</wps/find/journaldescription.cws_home/253/authorinstructions?navopenmenu=-2>
	

	Journal information

	Product description
</wps/find/journaldescription.cws_home/253/description#description> 	

	Editorial board
</wps/find/journaleditorialboard.cws_home/253/editorialboard#editorialboard>
	

	Audience </wps/find/journalaudience.cws_home/253/description#audience> 	

	Abstracting/indexing
</wps/find/journalabstracting.cws_home/253/abstracting#abstracting> 	

	Special issues and supplements
</wps/find/journalspecialissues.cws_home/253/specialissues#specialissues> 	

	Subscription information

	Bibliographic and ordering information
</wps/find/journalbibliographicinfo.cws_home/253/description#bibliographicinfo>
	

	Conditions of sale
</wps/find/journalconditionsofsale.cws_home/253/conditionsofsale#conditionsofsale>
	

	Dispatch dates
</wps/find/journaldispatchdates.cws_home/253/dispatchdates#dispatchdates> 	

	Journal-related information

	Contact the publisher
</wps/find/journalcontactpublisher.cws_home/253/contactpublisher#contactpublisher>
	

	Impact factor
</wps/find/journalimpactfactors.cws_home/253/description#impactfactors> 	

	Most downloaded articles
<javascript:openWindow("http://top25.sciencedirect.com/?journal_id=01615890","topdownload")>
	

	Other journals in same subject area
</wps/find/products_in_subject_and_group.cws_home/253> 	

	Support & contact </wps/find/supportfaq.cws_home/overview> 	

	About Elsevier </wps/find/intro.cws_home/ataglance> 	

	Select your view
</wps/find/journaldescription.cws_home/253/authorinstructions?navopenmenu=4>
	

	

			
	
	MOLECULAR IMMUNOLOGY	
		
	
Please bookmark this URL: http://www.elsevier.com/locate/molimm



*Guide for Authors*

/Molecular Immunology/ publishes Review articles, Research Reports,
Short Communications and Brief Structural Data Reports. Nucleotide
Sequence papers may also be submitted, but see below regarding prior
submission of sequence data to the EMBL Nucleotide Sequence Database.

The preferred medium of submission is online submission (see *Online
submission of papers*) or, if that is not possible, on disk with
accompanying manuscript (see "Electronic Submission")

*Online submission of papers*
Authors are requested to submit their manuscripts electronically, by
using the EESubmit submission tool at http://ees.elsevier.com/mimm/.
After registration, authors will be asked to upload their article and
associated artwork. The submission tool will generate a PDF file to be
used for the reviewing process. The submission tool generates an
automatic reply which incorporates the manuscript number for future
correspondence.Full instructions on how to use the online submission
tool are available at the above web address. For those authors who
cannot submit via EES, please refer to the appropriate Editor as he/she
may be able to assist with the (technical) submission problem.
*Submission of Papers*
Submission of a paper implies that it has not been published previously,
that it is not under consideration for publication elsewhere, and that
if accepted it will not be published elsewhere in the same form, in
English or in any other language, without the written consent of the
publisher. Publication shall not imply the concurrence of the Editors or
Publishers with the authors'interpretation, conclusions or validity of data.

Authors must include a cover letter that contains the title, authors, a
brief outline of the work's originality, desired section of publication,
corresponding author's name, address, telephone and fax numbers
(including country and city codes), and e-mail address. All categories
of submission should be submitted with a covering letter of transmittal
stating the category or section of preference in the Journal. The letter
should also give the name and address of the person to whom all
subsequent correspondence should be directed.

*Manuscript Preparation*
*General:* Manuscripts must be submitted in English and be typewritten,
double-spaced with wide margins on one side of white paper. Good quality
printouts with a font size of 12 or 10 pt are required. The
corresponding author should be identified (include a Fax number and
E-mail address). Full postal addresses must be given for all co-authors.
Authors should consult a recent issue of the journal for style if
possible. An electronic copy of the paper should accompany the final
version. The Editors reserve the right to adjust style to certain
standards of uniformity. Authors should retain a copy of their
manuscript since we cannot accept responsibility for damage or loss of
papers. Original manuscripts are discarded one month after publication
unless the Publisher is asked to return original material after use. It
is important to all concerned that a manuscript be carefully read for
errors and clarity before sending it to an Editor. Presentation of data
in duplicate form should be avoided and manuscripts will be scanned for
excessive length.

It is strongly recommended that authors follow the IMGT Scientific chart
(numbering and nomenclatrure) of immunoglobulin and T cell receptor
sequences of human and other vertebrate species. These rules and
sequences are available at IMGT, the international ImMunoGeneTics
information system ttp://imgt.cines.fr

*Abstracts:* All papers must have an accompanying abstract in English.

*Text:* Follow this order when typing manuscripts: Title, Authors,
Affiliations, Abstract, Keywords, Main text, Acknowledgements, Appendix,
References, Figure Captions and then Tables. Manuscripts dealing with
experimental work should be divided into major sections such as:
Introduction (optional), Experimental (with Materials, Methods and
Results) followed by Discussion, Conclusions and References. Do not
import the Figures or Tables into your text. The corresponding author
should be identified with an asterisk and footnote. All other footnotes
(except for table footnotes) should be identified with superscript
Arabic numbers. Footnotes should be typed at the bottom of the page on
which they appear. If a large number of abbreviations are used e.g.
sRNA, EA, Ag, EEM etc., it is advisable to include a glossary defining
such terms.

*Instructions regarding GenBank/DNA sequence linking.*
*DNA sequences and GenBank Accession numbers*
Many Elsevier journals cite "gene accession numbers" in their running
text and footnotes. Gene accession numbers refer to genes or DNA
sequences about which further information can be found in the database
at the National Center for Biotechnical Information (NCBI) at the
National Library of Medicine. Elsevier authors wishing to enable other
scientists to use the accession numbers cited in their papers via links
to these sources, should type this information in the following manner":

/For each and every/ accession number cited in an article, authors
should type the accession number in * _bold, underlined text._ * Letters
in the accession number should always be capitalised. (See Example 1
below). This combination of letters and format will enable Elsevier's
typesetters to recognize the relevant texts as accession numbers and add
the required link to GenBank's sequences.

*Example 1*: "GenBank accession nos. *AI631510, AI631511, AI632198,* and
*BF223228*, a B-cell tumor from a chronic lymphatic leukemia (GenBank
accession no. *BE675048*, and a T-cell lymphoma (GenBank accession no.
*AA361117*)".

Authors are encouraged to check accession numbers used very carefully.
*An error in a letter or number can result in a dead link.*

In the final version of the / *printed* / *article*, the accession
number text will not appear bold or underlined (see Example 2 below).

*Example 2*: "GenBank accession nos. AI631510, AI631511, AI632198, and
BF223228), a B-cell tumor from a chronic lymphatic leukemia (GenBank
accession no. BE675048), and a T-cell lymphoma (GenBank accession no.
AA361117)".

In the final version of the * /electronic/ copy*, the accession number
text will be linked to the appropriate source in the NCBI databases
enabling readers to go directly to that source from the article (see
Example 3 below).

*Example 3*: "GenBank accession nos. AI631510, AI631511, AI632198, and
BF223228), a B-cell tumor from a chronic lymphatic leukema (GenBank
accession no. BE675048), and a T-cell lymphoma (GenBank accession no.
AA361117)".

*References:* All publications cited in the text should be presented in
a list of references following the text of the manuscript. In the text
refer to the author's name (without initials) and year of publication
(e.g. "Since Peterson (1993) has shown that?" or "This is in the
agreement with results obtained later (Kramer, 1994)"). For three or
more authors use the first author followed by "/et al/.", in the text.
The list of references should be arranged alphabetically by authors'
names. The manuscript should be carefully checked to ensure that the
spelling of authors' names and dates are exactly the same in the text as
in the reference list.

References should be given in the following form:

Nadel, B., Tang, A., Feeney, A.J., 1998. VH replacement is unlikely to
contribute significantly to receptor editing due to an ineffectual
recombination of signal sequence. Mol. Immunol. 35, 227-232.

Varmus, H.E., Brown, P.O., 1989. Retroviruses. In: Berg, D.E., Howe,
M.M. (Eds.), Mobile DNA. American Society for Microbiology, Washington,
DC, pp. 253-272.

Strunk Jr.,W., White, E.B., 1979. The elements of style, 3rd Edition.
Macmillan, New York.

*Illustrations:* All illustrations should be provided in camera-ready
form, suitable for reproduction (which may include reduction) without
retouching. A complete set of labelled figures and illustrations should
accompany each copy of the manuscript. Photographs, charts and diagrams
are all to be referred to as "Figure(s)" and should be numbered
consecutively in the order to which they are referred. They should
accompany the manuscript, but should not be included within the text.
All illustrations should be clearly marked on the back with the figure
number and the author's name. All figures are to have a caption.
Captions should be supplied on a separate sheet. Particular attention
should be given to the size of the lettering to avoid unduly small
letters in the Published version.

/Immunoelectrophoretic patterns and other optical patterns/ should
normally be provided in the form of photographic reproductions of the
actual pattern, not as line drawings. Optical patterns (gel diffusion,
immunoelectrophoresis, Ouchterlony) should be labelled with symbols
which are descriptive of the materials employed and which do not require
reference to the legend for their identification. The position of
figures or illustrations should be indicated on the manuscript.

/Line drawings:/ Good quality printouts on white paper produced in black
ink are required. All lettering, graph lines and points on graphs should
be sufficiently large and bold to permit reproduction when the diagram
has been reduced to a size suitable for inclusion in the journal.
Dye-line prints or photocopies are not suitable for reproduction. Do not
use any type of shading on computer-generated illustrations. The
following standard symbols should be used on line diagrams: + × [] [] ˘
˘ ˘ ˘

/Photographs:/ Two original photographs must be supplied as they are to
be reproduced (e.g. black and white or colour). If necessary, a scale
should be marked on the photograph. Please note that photocopies of
photographs are not acceptable.

/Colour:/ Authors will be charged for colour at current printing costs.

/Colour illustrations for Journals with Colourful e-Product/
Submit colour illustrations as original photographs, high-quality
computer prints or transparencies, close to the expected in publication,
or as 35 mm slides. Please make sure the artwork is in an acceptable
format (TIFF, EPS, or MS Office files) and is at the correct resolution.
Polaroid colour prints are /not/ suitable. If, together with your
accepted article, you submit usable colour figures then Elsevier will
ensure, at no additional charge, that these figures will appear in
colour on the web (e.g., ScienceDirect and other sites) regardless of
whether or not these illustrations are reproduced in colour in the
printed version. For colour reproduction in print, you will receive
information regarding the costs from Elsevier after receipt of your
accepted article. For further information on the preparation of
electronic artwork, please see http://authors.elsevier.com/artwork.

*Tables:* Tables should each be typed on a separate page, numbered
consecutively, and each given a suitable, concise caption which should
clearly present the subject matter. Footnotes to tables should be typed
below the table and should be referred to by superscript lowercase
letters. No vertical rules should be used. Tables should not duplicate
results presented elsewhere in the manuscript (e.g. in graphs), and
should be intelligible without reference to the text.
*Nucleotide Sequences.* All DNA and amino acid sequence data must be
submitted, prior to publication, to the EMBL Nucleotide Sequence
Database. Instructions on how to submit data, plus Sequence Data
Submission Forms can be obtained from the following address:

EMBL Nucleotide Sequence Submissions
European Bioinformatics Institut
Hinxton Hall, Hinxton
Cambridge, CB10 1RQ, UK
Tel: +44 (0) 1223 494401
Fax: +44 (0) 1223 494472
E-mail: DATASUBS@EBI.AC.UK <mailto:DATASUBS@EBI.AC.UK>

Authors will be required to provide confirmation of submission of their
data (accession number) when returning their proofs.

*Proofs*
Proofs will be sent to the author (first-named author if no
corresponding author of a multi-authored paper is identified) by PDF
wherever possible and should be returned within 48 hours of receipt,
preferably by e-mail. Corrections should be restricted to typesetting
errors; any other amendments made may be charged to the author. Any
queries should be answered in full. Elsevier will do everything possible
to get your article corrected and published as quickly and accurately as
possible. Therefore, it is important to ensure that all of your
corrections are returned to us in one all-inclusive e-mail or fax.
Subsequent additional corrections will not be possible, so please ensure
that your first communication is complete. Should you choose to mail
your corrections, please return them to: Log-in Department, Elsevier,
Stover Court, Bampfylde Street, Exeter, Devon EX1 2AH, UK.

*Offprints*
Twentyfive (25) free offprints will be supplied to the corresponding
author of each article. Additional offprints and copies of the issue can
be ordered at a specially reduced rate using the order form sent to the
corresponding author after the manuscript has been accepted. Orders for
reprints (produced after publication of an article) will incur a 50%
surcharge.

*Copyright*
All authors must sign the "Transfer of Copyright" agreement before the
article can be published. This transfer agreement enables Elsevier Ltd
to protect the copyrighted material for the authors, without the author
relinquishing his/her proprietary rights. The copyright transfer covers
the exclusive rights to reproduce and distribute the article, including
reprints, photographic reproductions, microfilm or any other
reproductions of a similar nature, and translations. It also includes
the right to adapt the article for use in conjunction with computer
systems and programs, including reproduction or publication in
machine-readable form and incorporation in retrieval systems. Authors
are responsible for obtaining from the copyright holder permission to
reproduce any material for which copyright already exists.

*Author Services*
For queries relating to the general submission of manuscripts (including
electronic text and artwork) and the status of accepted manuscripts,
please contact Author Services, Log-in Department, Elsevier, The
Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK. E-mail:
authors@elsevier.co.uk <mailto: %0Aauthors@elsevier.co.uk>, Fax:
(+44)1865 843905, Tel: (+44)1865 843900.
Authors can also keep track of the progress of their accepted article,
and set up e-mail alerts informing them of changes to their manuscript's
status, by using the "Track a Paper" feature on External link
http://www.elsevier.com/authors.

	
		

		

		
	
Printer-friendly version <javascript:openPrinterFriendlyPage()>
  Printer-friendly version <javascript:openPrinterFriendlyPage()>

	

		

		
	
	
 Home </wps/find/homepage.cws_home> | Site map
</wps/find/sitemap.cws_home/sitemap> | Privacy policy
</wps/find/privacypolicy.cws_home/privacypolicy> | Terms and Conditions
</wps/find/termsconditions.cws_home/termsconditions> | Feedback
</wps/find/feedbackform.cws_home> | A Reed Elsevier
<http://www.reed-elsevier.com> company 	
 Copyright © 2007 Elsevier B.V. </wps/find/homepage.cws_home> All rights
reserved.

	

